Bank Of New York Mellon Corp Caribou Biosciences, Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$4.3 - $7.78 $799,774 - $1.45 Million	185,994 New	185,994 $988 Million
Q4 2022 Feb 14, 2023	BUY	$5.57 - $11.01 $1.05 Million - $2.08 Million	189,344 New	189,344 $1.19 Million
Q3 2022 Nov 14, 2022	BUY	$5.34 - $12.79 $183,087 - $438,517	34,286 Added 23.29%	181,471 $1.91 Million
Q2 2022 Aug 15, 2022	BUY	$5.1 - $9.74 $30,207 - $57,690	5,923 Added 4.19%	147,185 $799,000
Q1 2022 May 11, 2022	BUY	$8.42 - $15.32 $618,255 - $1.12 Million	73,427 Added 108.24%	141,262 $1.3 Million
Q4 2021 Feb 11, 2022	BUY	$14.59 - $23.26 $287,481 - $458,315	19,704 Added 40.94%	67,835 $1.02 Million
Q3 2021 Nov 12, 2021	BUY	$15.75 - $30.29 $758,063 - $1.46 Million	48,131 New	48,131 $1.15 Million

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $119M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.